35 years of translational neuroscience.

Picower Professor of Neuroscience in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences at MIT.

HHMI Investigator 1994–2015; Director of the Picower Institute 2007–2009. Member of the National Academy of Medicine.

Before moving to MIT in 2003, he served 17 years on the faculty of Brown University and the Brown University School of Medicine.

His foundational discoveries linking mGluR5 signaling to Fragile X biology helped define an entire field of neurodevelopmental therapeutics.

Previously founded Seaside Therapeutics, which advanced arbaclofen through Phase 3 trials in Fragile X Syndrome.

Member of the Translational Medicine Advisory Board of the Rett Syndrome Research Trust, advisory boards of EU-AIMS and the Translational Neuroscience Center at Boston Children's Hospital.

In industry, led translational medicine teams responsible for eight IND submissions and dozens of GCP-compliant clinical trials.

Prior academic faculty appointments at the University of Washington and Wake Forest University in anesthesiology, pain management, and translational medicine.

Mads Emil Matthiesen is a life sciences executive and entrepreneur with experience scaling healthcare companies from early innovation to clinical adoption and commercial traction. He is CEO, co-founder of CathVision, co-founder of FindZebra, and contributes to Allos Pharma's strategy, financing, and company development.

Paul Wang, M.D., is a developmental-behavioral pediatrician and autism expert with deep experience across academia, industry, and the non-profit sector. As an executive at Seaside Therapeutics, he led the design and execution of pioneering Phase 2 and 3 trials in autism and Fragile X syndrome.

At Autism Speaks and now at the Simons Foundation, Paul has led advocacy, awareness, and science funding efforts related to autism.

From 2020-2024, Paul was a federally-appointed member of the Interagency Autism Coordinating Committee.

With more than 40 years of experience, Ms. Walton-Bowen is an experienced biostatistical analysis, clinical operations and development leader who supports Allos in program development and execution, vendor management, and cross-functional coordination. She has deep experience managing all aspects of the arbaclofen development program worldwide over the past 15 years, first at Seaside Therapeutics and then at the Simons Foundation.

She has worked in big pharma (AstraZeneca, Merck), small pharma, and biotechnology (Genzyme) across multiple rare disease and neuroscience programs and brings deep operational insight into clinical planning and execution, manufacturing, regulatory documentation, and oversight of CRO relationships.

Her experience ensures continuity, quality, and timely delivery of key program milestones worldwide.

Mark is a highly experienced pharmaceutical regulatory executive. He brings more than 30 years of industry experience on both the Sponsor and consulting sides of the business, with expertise in many therapeutic areas including psychiatry, neurology, cardiovascular, diabetes, metabolic, inflammation, oncology, dermatology and nephrology.

In May 2023 Mark co-Founded Quantum Regulatory Solutions, a specialized Regulatory consulting company. Prior to consulting, Mark worked for three major pharmaceutical companies (Pfizer, Pharmacia and Novartis) in roles of increasing responsibility.

Mark excels at building and leading Regulatory teams, full business financial management, and providing expert Regulatory consulting services. Mark received a Doctor of Pharmacy Degree from the University of Michigan College of Pharmacy.